CuraVac Overview
- Year Founded
-
2002
- Status
-
Private
- Employees
-
6
- Latest Deal Type
-
2ndary - Private
- Investors
-
2
CuraVac General Information
Description
Developer of therapeutic vaccines designed to treat autoimmune diseases. The company develops vaccines to cure sclerosis, diabetes, rheumatoid arthritis and systemic lupus erythematosus, enabling patients by providing treatment and potential cure for myasthenia gravis, a debilitating autoimmune disease.
Contact Information
Website
www.curavac.comCorporate Office
- Avenue de Villefranche 80
- 1330 Rixensart
- Belgium
Corporate Office
- Avenue de Villefranche 80
- 1330 Rixensart
- Belgium
CuraVac Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 6. Secondary Transaction - Private | Completed | Generating Revenue | ||||
| 5. Grant | 01-Nov-2019 | Completed | Generating Revenue | |||
| 4. Angel (individual) | 21-Jun-2016 | Cancelled | Generating Revenue | |||
| 3. Accelerator/Incubator | 01-Jan-2014 | Completed | Generating Revenue | |||
| 2. Grant | $9M | $2.4M | Completed | Generating Revenue | ||
| 1. Angel (individual) | 01-Jan-2008 | $2.4M | $2.4M | Completed | Generating Revenue |
CuraVac Comparisons
Industry
Financing
Details
CuraVac Competitors (56)
One of CuraVac’s 56 competitors is Baliopharm, a Venture Capital-Backed company based in Basel, Switzerland.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Baliopharm | Venture Capital-Backed | Basel, Switzerland | ||||
| AnTolRx | Formerly VC-backed | Cambridge, MA | ||||
| Inovio Pharmaceuticals | Corporation | Plymouth Meeting, PA | ||||
| Xenikos | Venture Capital-Backed | Nijmegen, Netherlands | ||||
| Prevail Therapeutics | Formerly VC-backed | New York, NY |
CuraVac Patents
CuraVac Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| EP-4297775-A1 | Carrier protein for peptide antigen | Pending | 26-Feb-2021 | ||
| US-20240148863-A1 | Carrier protein for peptide antigen | Pending | 26-Feb-2021 | ||
| WO-2022180263-A1 | Carrier protein for peptide antigen | Inactive | 26-Feb-2021 | ||
| EP-4298224-A2 | Method for producing a periplasmic form of the protein crm197 | Pending | 26-Feb-2021 | ||
| US-20250326804-A1 | Method for producing a periplasmic form of the protein crm197 | Inactive | 26-Feb-2021 | C07K14/34 |
CuraVac Signals
CuraVac Investors (2)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Angel (individual) | Minority | |||
| European Commission | Government |
CuraVac FAQs
-
When was CuraVac founded?
CuraVac was founded in 2002.
-
Where is CuraVac headquartered?
CuraVac is headquartered in Rixensart, Belgium.
-
What is the size of CuraVac?
CuraVac has 6 total employees.
-
What industry is CuraVac in?
CuraVac’s primary industry is Drug Discovery.
-
Is CuraVac a private or public company?
CuraVac is a Private company.
-
What is CuraVac’s current revenue?
The current revenue for CuraVac is .
-
How much funding has CuraVac raised over time?
CuraVac has raised $2.4M.
-
Who are CuraVac’s investors?
and European Commission have invested in CuraVac.
-
Who are CuraVac’s competitors?
Baliopharm, AnTolRx, Inovio Pharmaceuticals, Xenikos, and Prevail Therapeutics are some of the 56 competitors of CuraVac.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process